The specific cytotoxicities of chimeric antigen receptor-engineered T cells on different lymphomas
10.3760/cma.j.issn.0253-2727.2017.10.004
- VernacularTitle: CD19嵌合抗原受体T细胞对不同淋巴瘤细胞杀伤活性的研究
- Author:
Rui ZHANG
1
;
Qi DENG
;
Songnan SUI
;
Xin JIN
;
Mingfeng ZHAO
Author Information
1. Department of Hematology and Oncology, Tianjin First Central Hospital, Tianjin 300192, China
- Publication Type:Journal Article
- Keywords:
Lymphomas;
Transcription, genetic;
Immunotherapy;
Chimeric antigen receptor
- From:
Chinese Journal of Hematology
2017;38(10):842-847
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the specific cytotoxicities of the second and third generations of chimeric antigen receptor (CAR) -engineered T cells (CAR-T) on different lymphomas.
Methods:CAR-Ts were prepared by lentivirus packaging and infection of T cells. CCK-8, ELISA and Lactate dehydrogenase cytotoxicity assay were applied to detect the proliferation capacity, the secretion level of inflammatory factor and the specific cytotoxicity. Flow cytometry assay showed the specific cytotoxicity and residual level of CAR-T in lymphomas of treated mice.
Results:The results showed that the third generation CAR-T had greater capacity of the specific cytotoxicity and proliferation capacity than of the second generation CAR-T. But there was no prominent change of the secretion level of inflammatory factor. The specific cytotoxicity of the second generation CAR-T on highly aggressive lymphomas Raji was more prominent than in inert EHEB, but also could achieve satisfactory effect. The tumor burden in the mice injected with Raji was lower than in the mice injected with EHEB from nude mice experiment. But the residual level of CAR-T in the EHEB-injected mice was higher than in the Raji-injected ones. So the second generation CAR-T was more suitable for the treatment of indolent lymphoma.
Conclusion:The second generation CD19 CAR-T could treat aggressive lymphoma in a relatively short period, while the second generation CD19 CAR-T need a longer time in vivo to achieve satisfactory curative effect on the noble lymphoma.
